GlassScriptPhysician profile
Aisha Khan
NPI 1902588213
$3,086.23
in general payments reported to CMS, 2019-2025
34 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $236 · 2024: $1,657 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,086.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $622.25 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $329.87 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $320.08 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Dexcom, INC. | $318.72 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.00 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $116.38 | 2024-2025 | |
| Medtronic, INC. | $101.01 | 2024 | Minimed 780g |
| Avadel Cns Pharmaceuticals, LLC | $88.60 | 2023-2025 | Lumryz |
| Sequel Med Tech, LLC | $85.62 | 2025 | Twiist |
| Corcept Therapeutics | $85.16 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $72.07 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Inspire Medical Systems, INC. | $72.01 | 2024-2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.58 | 2024-2025 | Xifaxan, Trulance |
| Amgen INC. | $56.79 | 2024-2025 | Repatha, Otezla, Otezla |
| Recordati_rare_diseases_inc. | $55.51 | 2025 | Isturisa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $54.50 | 2024 | Rexulti |
| Exact Sciences Corporation | $47.40 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $45.59 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $41.88 | 2025 | Spravato |
| Pfizer INC. | $38.80 | 2024 | |
| Esperion Therapeutics, INC. | $35.12 | 2023-2024 | Nexletol |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.17 | 2025 | Rexulti |
| Seqirus USA INC | $25.68 | 2025 | Fluad, Flucelvax |
| Neurocrine Biosciences, INC. | $23.63 | 2025 | |
| Phathom Pharmaceuticals, INC. | $22.76 | 2024 | Voquezna |
| Kyowa Kirin, INC. | $22.53 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $21.81 | 2023 | |
| Xeris Pharmaceuticals, INC. | $21.71 | 2024 | Gvoke Hypopen |
| Philips North America LLC | $20.89 | 2024 | (Ck7) Extended Holter |
| Cipher Pharmaceuticals US LLC | $20.47 | 2025 | Natroba, Spinosad |
| Kowa Pharmaceuticals America, INC. | $18.72 | 2024 | Livalo |
| Olympus America INC. | $15.10 | 2024 | Olympus |
| Ibsa Pharma INC. | $14.60 | 2025 | Tirosint, Flector, Licart |
| Beta Bionics, INC. | $12.22 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.